Sartorius Stedim Biotech share falls 2%, ranking among the weakest performers in the SBF 120
Sartorius Stedim Biotech is posting a marked decline this Monday, while the SBF 120 remains nearly stable. The share has fallen below its 20-day moving average, erasing part of the monthly rebound, and is now among the index's worst performers in the session.
A decline that pushes the share back below its MM20 and moves it further away from the 197.90 € resistance level
Sartorius Stedim Biotech is down 2.1% to 186.30 € in session, compared to the previous close of 190.30 €. The move places the share below its MM20 at 187.78 €, representing a negative spread of 0.79%, whereas it had remained comfortably above this benchmark during previous sessions. This slip comes after the share had already declined nearly 3% on Friday, September 4, bringing the weekly decline to nearly 5.8% while the monthly performance remains positive at around 7%.
However, the share remains above its MM50 (181.10 €, spread of +2.87%) and its MM200 (182.62 €, spread of +2.02%), reflecting intact medium-term momentum despite the short-term correction. The RSI at 65 remains distant from oversold territory and does not signal excessive selling pressure; today's pressure rather reflects a pullback following the approach to the 197.90 € resistance level, which was briefly breached in late August before being abandoned. The ranking of 111 out of 120 within the SBF 120 confirms that the stock is among the index's steepest declines in this session.
A stretched valuation in a heavy macro context for high-PER assets
In terms of valuations, according to the consensus of analysts surveyed, the share is trading at approximately 37.4 times expected earnings for the current fiscal year and 31.3 times those for the following fiscal year, multiples that make it sensitive to any tightening of financial conditions. Yet the macro context at this start of the academic year is particularly heavy: in the United States, the August employment report, which came in stronger than expected, led markets to incorporate an increased probability of another Fed rate hike at the meeting on September 15 and 16. A rise in policy rates mechanically weighs on growth stocks with high PER multiples, of which Sartorius Stedim Biotech is part.
Furthermore, tensions around the Strait of Hormuz maintain a risk premium on energy and consumer prices, reinforcing the scenario of persistently restrictive rates. In this context, the technical support at 162.70 € remains the main lower reference point to monitor if the correction were to continue, while resistance at 197.90 € represents the hurdle to overcome to regain the upward momentum that prevailed in late August.
